Persistent symptoms in adulthood | P value | ||||
Yes, n=33 | No, n=147 | ||||
Median | Q1, Q3 | Median | Q1, Q3 | ||
Age, years | 10.1 | 4.8, 14.2 | 9.5 | 5.8, 13.6 | 0.716 |
Year of diagnosis | 1995 | 1982, 2004 | 1999 | 1987, 2004 | 0.270 |
Haemoglobin, g/L | 123 | 117, 131 | 124 | 113, 132 | 0.677 |
EmA/ARA§, titre | 1:500 | 1:100, 1:2000 | 1:200 | 1:100, 1:1000 | 0.131 |
TGA, U/mL | 86 | 26, 120 | 76 | 33, 120 | 0.876 |
n | % | n | % | ||
Girls | 24 | 73 | 101 | 69 | 0.651 |
Main clinical presentation | 0.905 | ||||
Screen-detected | 6 | 18 | 28 | 19 | |
Gastrointestinal | 19 | 58 | 78 | 53 | |
Extra-intestinal | 8 | 24 | 40 | 27 | |
Severity of symptoms‡ | 0.851 | ||||
None | 8 | 30 | 33 | 30 | |
Mild | 11 | 41 | 39 | 35 | |
Moderate or severe | 8 | 30 | 38 | 35 | |
Specific symptoms | |||||
Abdominal pain | 10 | 37 | 59 | 48 | 0.302 |
Anaemia | 13 | 41 | 40 | 29 | 0.200 |
Arthralgia* | 1 | 5 | 6 | 7 | 1.000 |
Constipation | 3 | 10 | 11 | 9 | 0.733 |
Diarrhoea | 14 | 47 | 58 | 46 | 0.950 |
Poor growth | 15 | 47 | 62 | 47 | 0.992 |
Skin symptoms† | 2 | 10 | 8 | 8 | 0.677 |
Vomiting | 2 | 7 | 13 | 10 | 0.737 |
Degree of villous atrophy | 0.330 | ||||
Partial | 8 | 30 | 39 | 29 | |
Subtotal | 8 | 30 | 57 | 43 | |
Total | 11 | 41 | 37 | 28 | |
Type 1 diabetes | 0 | 0 | 8 | 7 | 0.356 |
*Data available for >80% of patients except in: 112.
†Data available for >80% of patients except in: 124.
‡Data available for >80% of patients except in: 137.
§Data available for >80% of patients except in: 130.
ARA, serum antireticulin antibodies; EmA, serum endomysium antibodies; Q1 and Q3, lower and upper quartiles; TGA, tissue transglutaminase antibodies.